Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.42 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27512419 | 0.85 | CSNK2A1 (0.59) | KDM4EALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL5584152 | 0.84 | KDM4E (0.65) | KDM4EALDH1A1MAPTHSD17B10KMT2A | |
| Methane SCHEMBL27891504 | 0.84 | CSNK2A1 (0.57) | KDM4EALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL7703619 | 0.80 | ALB (0.44) | KDM4EALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL3621261 | 0.80 | CA12 (0.50) | KDM4EALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL8121953 | 0.79 | AR (0.62) | KDM4EALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL30538373 | 0.76 | NPC1 (0.45) | KDM4EALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL5585019 | 0.76 | MAPT (0.62) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL5584615 | 0.76 | NPC1 (0.51) | KDM4EALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL10509414 | 0.74 | ALDH1A1 (0.64) | ALDH1A1KMT2AMAOAAKR1C3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| CN-101611041-A | Condensed heterocyclic compouds | TAKEDA PHARMACEUTICAL (JP) | 2009-12-23 | — | — | CN | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| CN-100347164-C | Benzofuryl derivatives and their use | HOFMMANN LA ROCHE AG F (CH) | 2007-11-07 | — | — | CN | disclosed |
| EP-0906301-B1 | BENZOFURYL DERIVATIVES AND THEIR USE | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-5955495-A | BENZOFURAN-2-CARBOXAMIDINE OR 2-CARBOXAMIDOXIME COMPOUNDS USEFUL IN THE CONTROL OR PREVENTION OF ILLNESSES OR DISORDERS OF THE CENTRAL NERVOUS SYSTEM SUCH AS MIGRAINE, SCHIZOPHRENIA, ANXIETY STATES, SLEEP DISORDERS, ANOREXIA, ALZHEIMER'S | HOFFMANN-LA ROCHE INC. (US) | 1999-09-21 | — | — | US | disclosed |
| CN-1217720-A | Benzofuryl derivatives and their use | HOFMMANN LA ROCHE (CH) | 1999-05-26 | — | — | CN | disclosed |
| EP-0906301-A1 | BENZOFURYL DERIVATIVES AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997042183-A1 | BENZOFURYL DERIVATIVES AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | KDM4E 621/4885ALDH1A1 2591/4885MAPT 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.